# Advisor Review - Advisor 2/3

**Role:** Academic advisor checking for fatal errors
**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** high
**Timestamp:** 2026-01-28T00:45:58.440914
**Response ID:** resp_08d0aad34c23719f0069794c749dc4819e9e3295a203accac9
**Tokens:** 51199 in / 369 out
**Response SHA256:** 01537396935507c2

---

I checked the draft strictly for **fatal** problems in (1) data–design alignment, (2) regression sanity, (3) completeness, and (4) internal consistency, as you requested. I did **not** evaluate prose, novelty, or “minor” specification choices.

### 1) DATA–DESIGN ALIGNMENT (CRITICAL)
- **Treatment timing vs data coverage:** All treatment cohorts are **≤ 2017** (in-force years 2011, 2012, 2013, 2016, 2017; Table 9), and the key outcome is the **May 2017** referendum. The panel uses referendums in **2000, 2003, 2016, 2017** (Section 5.4; Appendix A.1). This is aligned.
- **Post-treatment observations:**
  - Cross-section (2017): treated and control observations clearly exist (N=716 treated, N=1,404 control; Table 3).
  - Spatial RDD: both sides of cutoff exist (Table 5 reports NL and NR in every spec).
  - Panel: the draft explicitly excludes BS from the C&S panel because its first post period is the last period (Table 14 note); for the remaining cohorts there are post observations (2016/2017).
- **Treatment definition consistency:** Treatment coding is consistently described as **in-force by May 21, 2017** (Abstract; Sections 3.2, 4.1; Table 9). The treated cantons listed in Table 1 match the treated set implied elsewhere (GR, BE, AG, BL, BS).

**No fatal data/design misalignment found.**

---

### 2) REGRESSION SANITY (CRITICAL)
I scanned all reported tables with estimates (Tables 4–8, 11–15, plus RDD robustness Table 12, covariate balance Table 6, power Table 13):

- **No impossible values** (no R² outside [0,1], no negative SEs, no NA/NaN/Inf in reported results).
- **No obviously broken magnitudes:** coefficients are in plausible percentage-point ranges; SEs are not astronomically large and are not >100× the coefficient in any reported table.
- **N is present** in each regression-style table (Table 4 includes N; Table 5 provides effective NL/NR; Table 6 provides N; Table 8 provides N; Appendix tables include N).

**No fatal regression-output anomalies found.**

---

### 3) COMPLETENESS (CRITICAL)
- No placeholders like **TBD/TODO/XXX/NA** in the main tables/figures shown.
- The methods described (OLS, spatial RDD, randomization inference, panel pre-trends) all have corresponding reported results and/or figures/tables (e.g., OLS Table 4; RDD Table 5 and Figure 7; RI Figure 12/Table 15; panel Table 7/Figure 13/Table 14/Figure 14).
- Figures/tables referenced in the excerpt appear to exist in the provided draft content (including appendices referenced).

**No fatal “unfinished paper” indicators found.**

---

### 4) INTERNAL CONSISTENCY (CRITICAL)
I checked that key numbers cited in text match the tables:
- Raw treated–control gap **−9.6 pp** matches Table 3 (47.9 vs 57.5).
- OLS with language controls around **−1.8 pp (SE≈1.9)** matches Table 4.
- Spatial RDD pooled **−2.73 (SE 1.10)** and same-language **−1.36 (SE 1.27)** match Table 5 and the abstract.
- RI two-tailed p≈**0.62** matches Figure 12/Table 15.
- Treatment timing (in-force) is consistent across narrative and Table 9.

The sign flip between Table 3 (Gemeinde-weighted) and Table 7 (canton-weighted) is explicitly acknowledged in Table 7 notes and therefore is not an internal-consistency violation.

**No fatal internal inconsistencies found.**

---

ADVISOR VERDICT: PASS